6 results about "Chlorhexidine digluconate" patented technology

The invention discloses liquid foundation suitable for sensitive skin and a preparation method, and belongs to the technical field of cosmetics. The invention relates to a liquid foundation suitable for sensitive skin. The liquid foundation comprises an active core component: 3-8% of an aloe barbadensis leaf extract; the base component comprises 45%-60% of A-phase raw materials, 25%-35% of B-phase raw materials and 8%-15% of C-phase raw materials; synergistic soothing and repairing components: 0.5%-1.2% of a purslane extract, 0.3%-0.8% of a crocus sativus flower extract and 0.2%-0.6% of a cardiospermum halicacabum flower and leaf extract; a low-irritation antibacterial auxiliary component: 0.01% to 0.05% of chlorhexidine digluconate; by adopting a synergistic antibacterial system of the aloe barbadensis leaf extract and the low-concentration chlorhexidine digluconate, while the dosage of a synthetic antibacterial agent is reduced, broad-spectrum efficient antibacterial is realized, and the sensitization rate of a human patch test is less than or equal to 0.1%; on the other hand, the plant-derived emulsifier is used for replacing part of the synthetic thickening agent and matched with the relieving and repairing effects of the peptide compound component, so that the overall irritation of the formula is further reduced, and the composition is further suitable for sensitive skin and barrier damaged skin to be used for a long time.

The invention provides an antibacterial dressing composition and a medical gynecological protection pad, and belongs to the technical field of medical dressings. The composition is prepared from 70 to 90 parts of water, 8 to 10 parts of polyethylene glycol, 4 to 6 parts of glycerol, 0.3 to 0.7 part of carbomer, 0.06 to 0.15 part of L-cysteine, 4 to 8 parts of chitosan quaternary ammonium salt, 0.3 to 0.8 part of panthenol, 0.4 to 0.7 part of tocopheryl acetate, 0.2 to 0.4 part of sodium hyaluronate, 0.1 to 0.3 part of chlorhexidine digluconate, 3 to 4 parts of polyvinylpyrrolidone, 1 to 5 parts of sodium alginate, 0.1 to 0.3 part of polysorbate, 0.6 to 0.9 part of luteoloside, 0.1 to 0.2 part of quercetin and 0.05 to 0.2 part of sophocarpidine. Chitosan quaternary ammonium salt and chlorhexidine digluconate are used as bactericidal components, quercetin and sophocarpidine are added to serve as bacteriostatic agents, and the bactericidal components, active components such as panthenol, tocopheryl acetate and galuteolin and a film-forming agent form a dispersion system. The antibacterial facial mask has remarkable antibacterial property, and has the effects of resisting inflammation, preserving moisture, promoting tissue repair and the like. The gynecological protection pad acts on the surface of vulva inflammation, and the exact treatment effect can be achieved.

The invention relates to the technical field of medical dressings, in particular to an anti-inflammatory liquid dressing and a preparation method thereof.The anti-inflammatory liquid dressing is prepared from, by mass, natural anti-inflammatory ingredients including 1-3% of baicalin, 1-2% of honeysuckle extract and 0.5-2% of asiaticoside; a synthetic anti-inflammatory component: 0.1 to 0.5% of chlorhexidine digluconate; film forming materials: 5%-10% of carboxymethyl chitosan and 2%-5% of polyvinylpyrrolidone (PVP); a humectant: 1-3% of hyaluronic acid and 2-5% of glycerin; the pH regulator is 0.5-1% of lactic acid or citric acid and is used for regulating the pH of the system to 4.5-5.5; the traditional Chinese medicine composition has the effects of combining natural components with synthetic components (efficient bacteriostasis), reducing the risk of drug resistance and inhibiting bacterial proliferation.

The group of inventions relates to the field of medicine, and more particularly to haemostatics and drugs for providing temporary haemostasis in the case of non-major bleeds. Proposed are a pharmaceutical composition containing tranexamic acid, chlorhexidine digluconate, bupivacaine, and water, in the following proportions: 13-16 wt.% tranexamic acid, 2.00 wt.% chlorhexidine digluconate, 0.5 wt.% bupivacaine, and 81.5-84.5 wt.% water, and a drug in aerosol or spray form comprising said pharmaceutical composition. Use of the group of inventions makes it possible to stop bleeds very quickly and reduce the risk of renewed bleeding. In addition, providing the drug in the form of an aerosol or spray allows easy and convenient use. The proposed composition and drug can be used for providing temporary haemostasis in the case of non-major bleeds in the fields of dentistry, veterinary medicine, military field medicine, disaster medicine, and the like.

The application discloses a preparation method of hyaluronic acid chlorhexidine with bacteriostatic effect, and comprises the following steps: S1) preparing a sodium hyaluronate solution with a mass fraction of 2-3%; S2) preparing a chlorhexidine digluconate solution with a mass fraction of 1-2%; S3) slowly adding the chlorhexidine digluconate solution in the step S2) into the sodium hyaluronate solution in the step S1) and stirring to react; S4) adding anhydrous ethanol pre-cooled to 4 DEG C into the reaction mixture and standing to precipitate; S5) filtering the precipitate by using a filter membrane and repeatedly washing the precipitate with ethanol solutions with volume ratios of 75%, 85% and 95% for 3-5 times in sequence; and S6) drying the obtained precipitate for 8-12 hours to obtain hyaluronic acid chlorhexidine. The application adopts specific process parameters and reaction conditions, controls the reaction temperature, pH value and ionic strength accurately, and combines the synergistic effect of mechanical stirring and magnetic stirring, so that the uniformity and controllability of the reaction are remarkably improved, and the grafting rate of the hyaluronic acid chlorhexidine product prepared by the method can reach more than 85%.

This invention provides an engineered microbial strain for the biosynthesis of syringin and its application. The engineered microbial strain includes a host microbial strain and HpaBC, COMT, and UGT72E2 co-expressed in the host microbial strain. This engineered microbial strain, in conjunction with p-coumarol fermentation, can biosynthesize syringin. This invention also provides an engineered microbial strain for the biosynthesis of syringin and its application. This engineered microbial strain includes a p-coumarol biosynthetic engineered microbial strain and HpaBC, COMT, and UGT72E2 co-expressed in the p-coumarol biosynthetic engineered microbial strain. The p-coumarol biosynthetic engineered microbial strain includes a host microbial strain and TAL, 4CL1, CCR, and ADH6 co-expressed in the host microbial strain. AroG is also co-expressed in the host microbial strain. fbr and TyrA fbr This engineered bacterium for the biosynthesis of syringin can achieve high-efficiency biosynthesis of syringin using a simple carbon source.